Home > Compound List > Product Information
Pemetrexed_Molecular_structure_CAS_150399-23-8)
Click picture or here to close

Pemetrexed

Catalog No. DB00642 Name DrugBank
CAS Number 150399-23-8 Website http://www.ualberta.ca/
M. F. C20H21N5O6 Telephone (780) 492-3111
M. W. 427.41064 Fax (780) 492-1071
Purity Email david.wishart@ualberta.ca
Storage Chembase ID: 524

SYNONYMS

IUPAC name
(2R)-2-{[4-(2-{2-amino-4-oxo-1H,4H,7H-pyrrolo[2,3-d]pyrimidin-5-yl}ethyl)phenyl]formamido}pentanedioic acid
IUPAC Traditional name
alimta
Brand Name
Alimta
Synonyms
LY231514
Pemetrexed Disodium

DATABASE IDS

PubChem CID 60843
CAS Number 150399-23-8
PubChem SID 46505640

PROPERTIES

Hydrophobicity(logP) -1.5

DETAILS

Description (English)
Item Information
Drug Groups approved; investigational
Description Pemetrexed (brand name Alimta?) is a chemotherapy drug manufactured and marketed by Eli Lilly and Company. Its indications are the treatment of pleural mesothelioma as well as non-small cell lung cancer.
Indication Used in combination with cisplatin for the treatment of malignant pleural mesothelioma in adults whose disease is unresectable or who otherwise are not candidates for potentially curative surgery. Also used as a monotherapy for the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) after prior chemotherapy
Pharmacology Preclinical studies have shown that pemetrexed inhibits the in vitro growth of mesothelioma cell lines (MSTO-211H, NCI-H2052). Studies with the MSTO-211H mesothelioma cell line showed synergistic effects when pemetrexed was combined concurrently with cisplatin.
Affected Organisms
Humans and other mammals
Biotransformation Metabolized by Cytochrome P450 Enzymes
Half Life 3.5 hours
Protein Binding 81%
Elimination Pemetrexed is not metabolized to an appreciable extent and is primarily eliminated in the urine, with 70% to 90% of the dose recovered unchanged within the first 24 hours following administration.
Distribution * 16.1 L
Clearance * 91.8 mL/min [Cancer patients with normal renal function receiving 0.2 to 838 mg/m2 infusion over a 10-minute period]
References
Rollins KD, Lindley C: Pemetrexed: a multitargeted antifolate. Clin Ther. 2005 Sep;27(9):1343-82. [Pubmed]
Lansiaux A, Lokiec F: [Pemetrexed: from preclinic to clinic] Bull Cancer. 2007;94 Spec No Actualites:S134-8. [Pubmed]
Fuld AD, Dragnev KH, Rigas JR: Pemetrexed in advanced non-small-cell lung cancer. Expert Opin Pharmacother. 2010 Jun;11(8):1387-402. [Pubmed]
Adjei AA: Pemetrexed (Alimta): a novel multitargeted antifolate agent. Expert Rev Anticancer Ther. 2003 Apr;3(2):145-56. [Pubmed]
External Links
Wikipedia
RxList
Drugs.com

REFERENCES

  • Rollins KD, Lindley C: Pemetrexed: a multitargeted antifolate. Clin Ther. 2005 Sep;27(9):1343-82. Pubmed
  • Lansiaux A, Lokiec F: [Pemetrexed: from preclinic to clinic] Bull Cancer. 2007;94 Spec No Actualites:S134-8. Pubmed
  • Fuld AD, Dragnev KH, Rigas JR: Pemetrexed in advanced non-small-cell lung cancer. Expert Opin Pharmacother. 2010 Jun;11(8):1387-402. Pubmed
  • Adjei AA: Pemetrexed (Alimta): a novel multitargeted antifolate agent. Expert Rev Anticancer Ther. 2003 Apr;3(2):145-56. Pubmed